Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients

Bone Marrow Transplantation volume 44, pages 35–41 (2009)Cite this article

Abstract

Bone loss is recognized as worsening the quality of life in long-term survivors of Allo-SCT. This study evaluated the risk factors associated with bone loss and the role of zoledronic acid in preventing bone loss in allogeneic recipients. Fifty-three patients who underwent HLA-matched Allo-SCT were evaluated for their bone mineral density (BMD) in the lumbar spine and femoral neck at regular intervals. Zoledronic acid (4 mg) was given i.v. to 18 patients (ZA patients) at 2 months after SCT and then every 3 months until 2 years. Grade 2–4 acute GVHD was associated with bone loss (odds ratio (OR)=4.90, 95% confidence interval (CI)=1.41–16.99; P=0.012) at 1 year after SCT, whereas extensive chronic GVHD and steroid use were both unfavorable prognostic factors (OR=9.00 and 7.22, 95% CI=1.52–53.40 and 1.44–36.22; P=0.016, respectively) in terms of osteopenia/osteoporosis at 2 years after transplantation. The use of zoledronic acid significantly prevented bone loss in the femoral neck as well as the spine (OR=0.18, 95% CI=0.05–0.69, P=0.012). Therefore, BMD measurements and the use of zoledronic acid are recommended in cases of GVHD or long-term steroid use after Allo-SCT to prevent bone loss and threatening skeletal events.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Gandhi MK, Lekamwasam S, Inman I, Kaptoge S, Sizer L, Love S et al. Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study. Br J Haematol 2003; 121: 462–468.

    Article  Google Scholar 

  2. Valimaki MJ, Kinnunen K, Volin L, Tahtela R, Loyttyniemi E, Laitinen K et al. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 1999; 23: 355–361.

    Article  CAS  Google Scholar 

  3. Stern JM, Sullivan KM, Ott SM, Seidel K, Fink JC, Longton G et al. Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant 2001; 7: 257–264.

    Article  CAS  Google Scholar 

  4. Tauchmanova L, Serio B, Del Puente A, Risitano AM, Esposito A, De Rosa G et al. Long-lasting bone damage detected by dual-energy X-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2002; 87: 5058–5065.

    Article  CAS  Google Scholar 

  5. Schimmer AD, Minden MD, Keating A . Osteoporosis after blood and marrow transplantation: clinical aspects. Biol Blood Marrow Transplant 2000; 6: 175–181.

    Article  CAS  Google Scholar 

  6. D′Souza AB, Grigg AP, Szer J, Ebeling PR . Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation. Intern Med J 2006; 36: 600–603.

    Article  Google Scholar 

  7. Schulte CM, Beelen DW . Bone loss following hematopoietic stem cell transplantation: a long-term follow-up. Blood 2004; 103: 3635–3643.

    Article  CAS  Google Scholar 

  8. Kananen K, Volin L, Laitinen K, Alfthan H, Ruutu T, Valimaki MJ . Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab 2005; 90: 3877–3885.

    Article  CAS  Google Scholar 

  9. Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Shin HJ et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone Marrow Transplant 2007; 40: 541–547.

    Article  CAS  Google Scholar 

  10. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267–276.

    CAS  PubMed  Google Scholar 

  11. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  12. Lee KH, Choi SJ, Lee JH, Lee JS, Kim WK, Lee KB et al. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica 2005; 90: 939–948.

    PubMed  Google Scholar 

  13. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–259.

    CAS  Google Scholar 

  14. Kanis JA, Seeman E, Johnell O, Rizzoli R, Delmas P . The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry. Osteoporos Int 2005; 16: 456–459, discussion 579–80.

    Article  Google Scholar 

  15. Banfi A, Podesta M, Fazzuoli L, Sertoli MR, Venturini M, Santini G et al. High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia. Cancer 2001; 92: 2419–2428.

    Article  CAS  Google Scholar 

  16. Marcus R, Wong M, Heath III H, Stock JL . Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 2002; 23: 16–37.

    Article  CAS  Google Scholar 

  17. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87: 3609–3617.

    Article  CAS  Google Scholar 

  18. Delmas PD . Treatment of postmenopausal osteoporosis. Lancet 2002; 359: 2018–2026.

    Article  CAS  Google Scholar 

  19. Massenkeil G, Fiene C, Rosen O, Michael R, Reisinger W, Arnold R . Loss of bone mass and vitamin D deficiency after hematopoietic stem cell transplantation: standard prophylactic measures fail to prevent osteoporosis. Leukemia 2001; 15: 1701–1705.

    Article  CAS  Google Scholar 

  20. Tauchmanova L, De Simone G, Musella T, Orio F, Ricci P, Nappi C et al. Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37: 81–88.

    Article  CAS  Google Scholar 

  21. Tauchmanova L, Ricci P, Serio B, Lombardi G, Colao A, Rotoli B et al. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2005; 90: 627–634.

    Article  CAS  Google Scholar 

  22. Neville-Webbe HL, Evans CA, Coleman RE, Holen I . Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006; 27: 92–103.

    Article  CAS  Google Scholar 

  23. Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008; 26: 4739–4745.

    Article  CAS  Google Scholar 

  24. Mundy GR, Yoneda T, Hiraga T . Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol 2001; 28 (2 Suppl 6): 35–44.

    Article  CAS  Google Scholar 

  25. Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J et al. Zoledronic acid treatment of 5T2 MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003; 18: 482–492.

    Article  CAS  Google Scholar 

  26. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M . Stimulation of gamma delta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96: 384–392.

    CAS  PubMed  Google Scholar 

  27. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G . Human T cell receptor gamma delta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197: 163–168.

    Article  CAS  Google Scholar 

  28. Tassone P, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli V et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000; 14: 841–844.

    Article  CAS  Google Scholar 

  29. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI . The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 1126–1134.

    Article  CAS  Google Scholar 

  30. Kuroda J, Kimura S, Segawa H, Kobayashi Y, Yoshikawa T, Urasaki Y et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 2003; 102: 2229–2235.

    Article  CAS  Google Scholar 

  31. Kimura S, Kuroda J, Segawa H, Sato K, Nogawa M, Yuasa T et al. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int J Hematol 2004; 79: 37–43.

    Article  CAS  Google Scholar 

  32. Fiegl M, Juergens M, Hiddemann W, Braess J . Cytotoxic activity of the third-generation bisphosphonate zoledronic acid in acute myeloid leukemia. Leuk Res 2007; 31: 531–539.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Republic of Korea

    Y S Chae, J G Kim, J H Moon, S N Kim, S J Lee, Y J Kim & S K Sohn

Authors
  1. Y S Chae
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J G Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J H Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S N Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S J Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y J Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S K Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S K Sohn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chae, Y., Kim, J., Moon, J. et al. Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients. Bone Marrow Transplant 44, 35–41 (2009). https://doi.org/10.1038/bmt.2008.414

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.414

Keywords

This article is cited by

Search

Advanced search

Quick links